{"title":"The World Ayurveda Congress – A movement for advancement of Ayurveda","authors":"Girish Tillu, Supriya Bhalerao, Pawankumar Godatwar","doi":"10.1016/j.jaim.2024.101123","DOIUrl":"10.1016/j.jaim.2024.101123","url":null,"abstract":"","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 101123"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ayurveda has unique and relevant methods in nosology, symptomatology, and drug selection. These methods need a novel and effective way of presentation for convenient comprehension and implementation. ‘Clinical algorithms’ is one such way, wherein a large amount of data is simplified, conceptual intricacies abstracted, and clinical application made easier. This article uses a modified version of the Horabin and Lewis algorithm to construct a clinical algorithm for Bhasma selection in the management of Pandu (anemia). The textual descriptions regarding the pathology and clinical presentations of Pandu have been compiled, and broadly classified, and the Bhasmas indication in suit each set of disease presentation has been specified. The algorithm is validated and optimized at single centre, while multicentre implementations and post-hoc modifications are warranted.
阿育吠陀在病名学、症状学和药物选择方面拥有独特而相关的方法。这些方法需要一种新颖有效的呈现方式，以便于理解和实施。临床算法 "就是这样一种方法，它简化了大量数据，抽象了复杂的概念，使临床应用更加容易。本文使用 Horabin 和 Lewis 算法的改进版，构建了治疗潘杜（贫血）的巴司马选择临床算法。本文对有关潘杜病理和临床表现的文字描述进行了汇编和大致分类，并明确指出了适合每种疾病表现的巴斯玛适应症。该算法在单个中心进行了验证和优化，而多中心实施和事后修改是有必要的。
{"title":"Proposed clinical algorithm for hematinic bhasmas selection for Ayurvedic pediatric care","authors":"K.P. Karthik , Arun Kumar Mahapatra , Prashant Kumar Gupta , S. Rajagopala","doi":"10.1016/j.jaim.2024.100972","DOIUrl":"10.1016/j.jaim.2024.100972","url":null,"abstract":"<div><div>Ayurveda has unique and relevant methods in nosology, symptomatology, and drug selection. These methods need a novel and effective way of presentation for convenient comprehension and implementation. ‘Clinical algorithms’ is one such way, wherein a large amount of data is simplified, conceptual intricacies abstracted, and clinical application made easier. This article uses a modified version of the Horabin and Lewis algorithm to construct a clinical algorithm for <em>Bhasma</em> selection in the management of <em>Pandu</em> (anemia). The textual descriptions regarding the pathology and clinical presentations of <em>Pandu</em> have been compiled, and broadly classified, and the <em>Bhasmas</em> indication in suit each set of disease presentation has been specified. The algorithm is validated and optimized at single centre, while multicentre implementations and post-hoc modifications are warranted.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 100972"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142702705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.jaim.2024.100994
Akshatha K. Bhat , Venugopalan Krishna kumar
This case is about an Episodic Cluster Headache (ECH) for 13 years treated effectively by Jaloukavacharana, Nasya and Ayurveda oral medications. It commenced with sudden episodic headache once or twice a day for a period of 40 days in a row, every year in the month of January and February. The pain intensity was 10/10 in numeric pain intensity scale, HIT -6 (Headache Impact Test) Score- 69, CHIQ (Cluster headache impact questionnaire) Score- 34 DASS 21 Scale- Depression- 8 anxiety-5 stress-11. Ayurveda treatment included one sitting of Jaloukavacharana and seven days of Kumkumadighrita Nasya. Drakshadi Kashaya, Soothashekararasa and Avipatthikara choorna were given internally. Patient reported no attacks of ECH thereafter with the HIT 6 score −36, CHIQ Score-0 and DASS-21 (Depression – 0, Anxiety-0, Stress- 0) after treatment. This line of treatment prevented the recurrence of ECH attacks with overall improvement in the quality of life without any known side effects.
{"title":"Prophylactic Ayurveda treatment for episodic cluster headache – A Case Report","authors":"Akshatha K. Bhat , Venugopalan Krishna kumar","doi":"10.1016/j.jaim.2024.100994","DOIUrl":"10.1016/j.jaim.2024.100994","url":null,"abstract":"<div><div>This case is about an Episodic Cluster Headache (ECH) for 13 years treated effectively by <em>Jaloukavacharana</em>, <em>Nasya</em> and <em>Ayurveda</em> oral medications. It commenced with sudden episodic headache once or twice a day for a period of 40 days in a row, every year in the month of January and February. The pain intensity was 10/10 in numeric pain intensity scale, HIT -6 (Headache Impact Test) Score- 69, CHIQ (Cluster headache impact questionnaire) Score- 34 DASS 21 Scale- Depression- 8 anxiety-5 stress-11. Ayurveda treatment included one sitting of <em>Jaloukavacharana</em> and <em>seven</em> days of <em>Kumkumadighrita Nasya. Drakshadi Kashaya, Soothashekararasa</em> and <em>Avipatthikara choorna</em> were given internally. Patient reported no attacks of ECH thereafter with the HIT 6 score −36, CHIQ Score-0 and DASS-21 (Depression – 0, Anxiety-0, Stress- 0) after treatment. This line of treatment prevented the recurrence of ECH attacks with overall improvement in the quality of life without any known side effects.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 100994"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The AYUSH 64 formulation helps to treat mild to moderate cases of COVID-19. Although several drugs have been proposed to combat COVID-19, no medication is available for SARS-CoV-2 infection. The RNA-dependent RNA polymerase (RdRp) is the pivotal enzyme of SARS-CoV-2 replication, so it could be considered a better drug target for experimental studies.
Objective
The AYUSH-64 formulation plants exhibited multiple therapeutic properties; thus, the present study aims to screen the phytocompounds of these plants against SARS CoV2 RdRp to identify specific compounds that could potentially affect COVID-19 infection.
Materials and methods
PatchDock and AutoDock tools were used for docking experiments. MD simulations and Density Functional Theory (DFT) calculations of protein-ligand Picroside-I and Remdesivir complexes were carried out in GROMACS v2019.4 and Gaussian 09 software, respectively.
Results
Among the tested, five phytocompounds (Picroside I, Oleanolic acid, Arvenin I, II, and III) from AYUSH-64 medicinal plants showed possible binding with RdRp catalytic residues (Ser759, Asp760, and Asp761). Of these, Picroside I exhibited hydrogen bond interactions with NTP entry channel residues (Arg553 and Arg555). The MM-PBSA free energy, RMSD, Rg, PCA, and RMSF analysis suggested that the Picroside I complex showed stable binding interactions with RdRp in the 50 ns simulation. In addition to this, Picroside I revealed its robust and attractive nature toward the target protein, as confirmed by DFT.
Conclusion
The results of this study have proposed that Picroside I from AYUSH 64 medicinal plant compounds was the selective binder of catalytic and NTP entry channel residues of SARS-CoV2 RdRp thereby; it may considered as a potential inhibitor of SARS-CoV2 RdRp.
{"title":"In silico exploration of phytocompounds from AYUSH-64 medicinal plants against SARS CoV-2 RNA-dependent RNA polymerase","authors":"Srinivasulu Cheemanapalli , Ramanjaneyulu Golla , Sudhakar Pagidi , Seshapani Pantangi","doi":"10.1016/j.jaim.2024.101026","DOIUrl":"10.1016/j.jaim.2024.101026","url":null,"abstract":"<div><h3>Background</h3><div>The AYUSH 64 formulation helps to treat mild to moderate cases of COVID-19. Although several drugs have been proposed to combat COVID-19, no medication is available for SARS-CoV-2 infection. The RNA-dependent RNA polymerase (RdRp) is the pivotal enzyme of SARS-CoV-2 replication, so it could be considered a better drug target for experimental studies.</div></div><div><h3>Objective</h3><div>The AYUSH-64 formulation plants exhibited multiple therapeutic properties; thus, the present study aims to screen the phytocompounds of these plants against SARS CoV2 RdRp to identify specific compounds that could potentially affect COVID-19 infection.</div></div><div><h3>Materials and methods</h3><div>PatchDock and AutoDock tools were used for docking experiments. MD simulations and Density Functional Theory (DFT) calculations of protein-ligand Picroside-I and Remdesivir complexes were carried out in GROMACS v2019.4 and Gaussian 09 software, respectively.</div></div><div><h3>Results</h3><div>Among the tested<strong>,</strong> five phytocompounds (Picroside I, Oleanolic acid, Arvenin I, II, and III) from AYUSH-64 medicinal plants showed possible binding with RdRp catalytic residues (Ser759, Asp760, and Asp761). Of these, Picroside I exhibited hydrogen bond interactions with NTP entry channel residues (Arg553 and Arg555). The MM-PBSA free energy, RMSD, Rg, PCA, and RMSF analysis suggested that the Picroside I complex showed stable binding interactions with RdRp in the 50 ns simulation. In addition to this, Picroside I revealed its robust and attractive nature toward the target protein, as confirmed by DFT.</div></div><div><h3>Conclusion</h3><div>The results of this study have proposed that Picroside I from AYUSH 64 medicinal plant compounds was the selective binder of catalytic and NTP entry channel residues of SARS-CoV2 RdRp thereby; it may considered as a potential inhibitor of SARS-CoV2 RdRp.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 101026"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gestational Diabetes Mellitus (GDM) is a metabolic condition that develops in course of pregnancy. The World Health Organization describes it as carbohydrate intolerance that causes hyperglycemia of varying severity and manifests itself or is first noticed during pregnancy. Early prediction is now possible, owing to the application of cutting-edge methods like machine learning.
Objective
In the proposed empirical study, different machine-learning algorithms are applied to predict the prospective risk factors influencing the progression of GDM in gestating mothers.
Materials and methods
The performance of these algorithms is evaluated through accuracy, precision, f1-score, etc. The lifestyle interventions and medications listed in Ayurveda literature are discussed for effective management of the disease.
Results
Most of the proposed classifiers achieved a reasonable accuracy range of 75–82 %. Appropriate lifestyle changes, herbal remedies, decoctions, and churnas have all been shown to be useful in lowering the risk of GDM. Early detection using machine learning models can significantly reduce disease severity by facilitating timely Ayurvedic interventions.
Conclusion
The proposed work is more focused on the identification of factors impacting GDM in expectant women. A balanced diet with physical exercise, proper medication, and better lifestyle management (through Garbini Paricharya) can control the perils of GDM if diagnosed prematurely.
{"title":"A machine learning-based clinical decision support system for effective stratification of gestational diabetes mellitus and management through Ayurveda","authors":"Nisha P. Shetty , Jayashree Shetty , Veeraj Hegde , Sneha Dattatray Dharne , Mamtha Kv","doi":"10.1016/j.jaim.2024.101051","DOIUrl":"10.1016/j.jaim.2024.101051","url":null,"abstract":"<div><h3>Background</h3><div>Gestational Diabetes Mellitus (GDM) is a metabolic condition that develops in course of pregnancy. The World Health Organization describes it as carbohydrate intolerance that causes hyperglycemia of varying severity and manifests itself or is first noticed during pregnancy. Early prediction is now possible, owing to the application of cutting-edge methods like machine learning.</div></div><div><h3>Objective</h3><div>In the proposed empirical study, different machine-learning algorithms are applied to predict the prospective risk factors influencing the progression of GDM in gestating mothers.</div></div><div><h3>Materials and methods</h3><div>The performance of these algorithms is evaluated through accuracy, precision, f1-score, etc. The lifestyle interventions and medications listed in Ayurveda literature are discussed for effective management of the disease.</div></div><div><h3>Results</h3><div>Most of the proposed classifiers achieved a reasonable accuracy range of 75–82 %. Appropriate lifestyle changes, herbal remedies, decoctions, and churnas have all been shown to be useful in lowering the risk of GDM. Early detection using machine learning models can significantly reduce disease severity by facilitating timely Ayurvedic interventions.</div></div><div><h3>Conclusion</h3><div>The proposed work is more focused on the identification of factors impacting GDM in expectant women. A balanced diet with physical exercise, proper medication, and better lifestyle management (through <em>Garbini Paricharya</em>) can control the perils of GDM if diagnosed prematurely.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 101051"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.jaim.2024.101015
Rajesh Shah , Gitanjali Talele , Nirmal Kumar Kasinathan , Madan Barkume , Jyoti Kode
Background
Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses.
Objectives
In this research, potentized preparations derived from biomaterial, referred to as nosodes, have exhibited promising effectiveness against cancer in laboratory experiments. This study seeks to further substantiate these findings by employing animal models.
Method
Potentized preparations from category nosodes sourced from biomaterials of HIV, Cancer tissue, Hepatitis C and a combination underwent testing within the NCI's preclinical evaluation protocols using Xenograft models (HOP62). All the experimental mice were randomly assigned to one of six groups (n = 6), including vehicle and positive controls. These preparations were administered orally at a dosage of 0.1 ml, five days a week, over a four-week period. The mice were closely monitored at regular intervals for 32 days, with observations regarding changes in body weight, tumor volume, morbidity, and mortality. Relative tumor volume (RTV) was calculated as the tumor volume on the day of measurement divided by the tumor volume on day 1.
Results
The groups treated with Hepatitis C 30c and HIV 100c nosodes have not shown effect with respect to Relative Tumor Volume (RTV). Evidence of significant tumor regression was observed for RTV on day 30 in groups treated with HIV nosode 30c (P = 0.002), and Cancer nosode 30c (P = 0.005). Percentage Survival was noted better in HIV nosode 30c treated group from day 25, however, in other groups survival percentage remained constant. Varied animal body weight in all groups was noted. Significant differences in tumor volume with respect to time in all treated groups were observed.
Conclusion
Results are suggestive of tumor regression which is encouraging to undertake further clinical trials to explore the anticancer potential of HIV nosode and Cancer nosode.
{"title":"Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model","authors":"Rajesh Shah , Gitanjali Talele , Nirmal Kumar Kasinathan , Madan Barkume , Jyoti Kode","doi":"10.1016/j.jaim.2024.101015","DOIUrl":"10.1016/j.jaim.2024.101015","url":null,"abstract":"<div><h3>Background</h3><div>Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses.</div></div><div><h3>Objectives</h3><div>In this research, potentized preparations derived from biomaterial, referred to as nosodes, have exhibited promising effectiveness against cancer in laboratory experiments. This study seeks to further substantiate these findings by employing animal models.</div></div><div><h3>Method</h3><div>Potentized preparations from category nosodes sourced from biomaterials of HIV, Cancer tissue, Hepatitis C and a combination underwent testing within the NCI's preclinical evaluation protocols using Xenograft models (HOP62). All the experimental mice were randomly assigned to one of six groups (n = 6), including vehicle and positive controls. These preparations were administered orally at a dosage of 0.1 ml, five days a week, over a four-week period. The mice were closely monitored at regular intervals for 32 days, with observations regarding changes in body weight, tumor volume, morbidity, and mortality. Relative tumor volume (RTV) was calculated as the tumor volume on the day of measurement divided by the tumor volume on day 1.</div></div><div><h3>Results</h3><div>The groups treated with Hepatitis C 30c and HIV 100c nosodes have not shown effect with respect to Relative Tumor Volume (RTV). Evidence of significant tumor regression was observed for RTV on day 30 in groups treated with HIV nosode 30c (P = 0.002), and Cancer nosode 30c (P = 0.005). Percentage Survival was noted better in HIV nosode 30c treated group from day 25, however, in other groups survival percentage remained constant. Varied animal body weight in all groups was noted. Significant differences in tumor volume with respect to time in all treated groups were observed.</div></div><div><h3>Conclusion</h3><div>Results are suggestive of tumor regression which is encouraging to undertake further clinical trials to explore the anticancer potential of HIV nosode and Cancer nosode.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 101015"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ayurveda treatment of nevus lipomatosus cutaneous superficialis through Ksharasutra: A case report","authors":"Ranjan Kumar Kasta , Ajit Kumar Pradhan , Priyanka Giri , Prasanta Kumar Sahoo","doi":"10.1016/j.jaim.2024.101031","DOIUrl":"10.1016/j.jaim.2024.101031","url":null,"abstract":"","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 101031"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ovarian cancer patients with BRCA1 mutation have more susceptibility for secondary breast cancer. In females with BRCA1 mutation, the risk of developing breast carcinoma is 65% and of ovarian cancer is 39%, before 70 years of age.
This is a case report of a 74 year old, post-menopausal woman diagnosed with metastatic retroperitoneal lymph node, high-grade papillary adenocarcinoma primary ovary stage IIIA in April 2004 at the age of 48 years. She underwent 3 cycles of neo-adjuvant chemotherapy Inj. Methotrexate and Inj. Carboplatin from June to August 2004 followed by optimum cytoreduction in September 2004. Later she completed 3 more cycles of chemotherapy of the same protocol from October to November 2004. Tab Etoposide was given from December 2004 to October 2006. In May 2006, during oral chemotherapy and with unremarkable radiological findings, the patient chose Ayurvedic treatment in view of immune boosting, and improving quality of life. The patient underwent 11 sets of Panchakarma treatment, almost every year, from December 2007 to September 2019. She was disease-free for 13 years leading a good quality of life with adjunct Ayurvedic treatment.
In October 2019, she was diagnosed with Left breast duct carcinoma with ER, PR hormone positive status. Her genetic mutation analysis report at that time revealed BRCA 1 mutation. She underwent Left Modified Radical Mastectomy in October 2019, followed by prophylactic Right Breast Mastectomy and oral hormonal therapy. Now she is living with better quality of life with adjunct Ayurvedic treatment, including Oral Ayurvedic Medicines possessing Rasayana (immunomodulatory) and hepato-protective activity and 12 sets of Panchakarma Chikitsa.
In this case of Stage IIIA Ovarian carcinoma and second primary Breast carcinoma with BRCA 1 genetic mutation (HBOC syndrome), a long-term 13 years of disease-free survival, and 20 years of overall survival is achieved with the integration of Ayurvedic treatment and conventional cancer treatment.
{"title":"Integration of Ayurvedic and Allopathic treatment in hereditary breast and ovarian cancer patient with Germline BRCA1 mutation for long term disease free survival: A case report","authors":"Sadanand Sardeshmukh, Vineeta Deshmukh, Arvind Kulkarni, Shweta Gujar, Vinita Awalkanthe, Nilambari Sardeshmukh, Bhagyashree Sardeshmukh, Dhananjay Deshpande, Anjali Deshpande, Sandeep Chavan","doi":"10.1016/j.jaim.2024.100999","DOIUrl":"10.1016/j.jaim.2024.100999","url":null,"abstract":"<div><div>Ovarian cancer patients with BRCA1 mutation have more susceptibility for secondary breast cancer. In females with BRCA1 mutation, the risk of developing breast carcinoma is 65% and of ovarian cancer is 39%, before 70 years of age.</div><div>This is a case report of a 74 year old, post-menopausal woman diagnosed with metastatic retroperitoneal lymph node, high-grade papillary adenocarcinoma primary ovary stage IIIA in April 2004 at the age of 48 years. She underwent 3 cycles of neo-adjuvant chemotherapy Inj. Methotrexate and Inj. Carboplatin from June to August 2004 followed by optimum cytoreduction in September 2004. Later she completed 3 more cycles of chemotherapy of the same protocol from October to November 2004. Tab Etoposide was given from December 2004 to October 2006. In May 2006, during oral chemotherapy and with unremarkable radiological findings, the patient chose Ayurvedic treatment in view of immune boosting, and improving quality of life. The patient underwent 11 sets of Panchakarma treatment, almost every year, from December 2007 to September 2019. She was disease-free for 13 years leading a good quality of life with adjunct Ayurvedic treatment.</div><div>In October 2019, she was diagnosed with Left breast duct carcinoma with ER, PR hormone positive status. Her genetic mutation analysis report at that time revealed BRCA 1 mutation. She underwent Left Modified Radical Mastectomy in October 2019, followed by prophylactic Right Breast Mastectomy and oral hormonal therapy. Now she is living with better quality of life with adjunct Ayurvedic treatment, including Oral Ayurvedic Medicines possessing <em>Rasayana</em> (immunomodulatory) and hepato-protective activity and 12 sets of <em>Panchakarma Chikitsa</em>.</div><div>In this case of Stage IIIA Ovarian carcinoma and second primary Breast carcinoma with BRCA 1 genetic mutation (HBOC syndrome), a long-term 13 years of disease-free survival, and 20 years of overall survival is achieved with the integration of Ayurvedic treatment and conventional cancer treatment.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 100999"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ayurvedic formulations need to be explored and tested with biomedical techniques. Polyherbal medicated ghee (Ghrita) are recommended for the management of epilepsy (Apasmara) and prepared using specialized process (Snehapaka), as per classical textbooks of Ayurveda. So, the present study deals with the systematic examination of the effect of different marketed formulations for treating Apasmara on convulsive impairment in Pentylenetetrazol (PTZ) induced seizures in mice.
Objective
To assess organoleptic, physicochemical, phytochemical and pharmacological activity of selected Ghrita formulations used to treat Apasmara.
Materials and Method
Six marketed Ghrita formulations used for Apasmara, such as Baidyanath Brahmi Ghrita (BBG), Patanjali Brahmi Ghrita, Kotakkal Brahmi Ghrita, Panchagavya Ghrita, Mahapanchagavya Ghrita and Nirgundyadi Ghrita were selected for the study. Selected Ghrita formulations were subjected to physicochemical analysis (following pharmacopeial procedures), phytochemical screening and pharmacological profile for quality and therapeutic efficacy. The screening parameters included pH, viscosity, specific gravity, loss on drying, acid value, saponification value, peroxide value, iodine value, refractive index and rancidity determination, and other phytochemical tests for secondary metabolites.
Results
BBG demonstrates superior protection against the onset and duration of convulsions compared to alternative Ghrita formulations. As evidenced by its efficacy in mitigating PTZ-induced convulsions, BBG stands out as the optimal choice for exerting potent anticonvulsant effects.
Conclusion
In-vivo screening suggests BBG as a potential Ghrita preparation for treatment of epilepsy.
{"title":"Organoleptic, physicochemical, phytochemical and pharmacological evaluation of six medicated ghee used for Ayurvedic management of Epilepsy","authors":"Snehal Moon , Nishikant Raut , Harshal Moon , Anmol Dhawande , Shailendra Gurav","doi":"10.1016/j.jaim.2024.100995","DOIUrl":"10.1016/j.jaim.2024.100995","url":null,"abstract":"<div><h3>Background</h3><div>Ayurvedic formulations need to be explored and tested with biomedical techniques. Polyherbal medicated <em>ghee</em> (<em>Ghrita</em>) are recommended for the management of epilepsy (<em>Apasmara</em>) and prepared using specialized process (<em>Snehapaka</em>), as per classical textbooks of Ayurveda. So, the present study deals with the systematic examination of the effect of different marketed formulations for treating <em>Apasmara</em> on convulsive impairment in Pentylenetetrazol (PTZ) induced seizures in mice.</div></div><div><h3>Objective</h3><div>To assess organoleptic, physicochemical, phytochemical and pharmacological activity of selected <em>Ghrita</em> formulations used to treat <em>Apasmara.</em></div></div><div><h3>Materials and Method</h3><div>Six marketed <em>Ghrita</em> formulations used for <em>Apasmara,</em> such as Baidyanath <em>Brahmi Ghrita</em> (BBG), Patanjali <em>Brahmi Ghrita</em>, Kotakkal <em>Brahmi Ghrita</em>, <em>Panchagavya Ghrita</em>, <em>Mahapanchagavya Ghrita</em> and <em>Nirgundyadi Ghrita</em> were selected for the study. Selected <em>Ghrita</em> formulations were subjected to physicochemical analysis (following pharmacopeial procedures), phytochemical screening and pharmacological profile for quality and therapeutic efficacy. The screening parameters included pH, viscosity, specific gravity, loss on drying, acid value, saponification value, peroxide value, iodine value, refractive index and rancidity determination, and other phytochemical tests for secondary metabolites.</div></div><div><h3>Results</h3><div>BBG demonstrates superior protection against the onset and duration of convulsions compared to alternative <em>Ghrita</em> formulations. As evidenced by its efficacy in mitigating PTZ-induced convulsions, BBG stands out as the optimal choice for exerting potent anticonvulsant effects.</div></div><div><h3>Conclusion</h3><div><em>In-vivo</em> screening suggests BBG as a potential <em>Ghrita</em> preparation for treatment of epilepsy.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 100995"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Primary dysmenorrhea (PD) is characterized by discomfort with no organic etiology (no pelvic disease), recurring pain, or lower abdominal cramps that start between the first 8–72 h of menstruation. Cupping therapy uses a tool to form a vacuum at certain points on the skin.
Objectives
We investigated the mechanism of pain relief caused by cupping therapy in primary dysmenorrhea that is played by cupping therapy in PD. This study aimed to investigate the effects of the cupping method on pain symptoms, changes in PGF2α, PGE, and β-endorphin levels, and uterine morphology in PD.
Methods
A total of 35 female rats were divided into five groups (n = 7 rats per group): control, PD, dysmenorrhea treated with dry cupping (DC), dysmenorrhea treated with wet cupping (WC), and dysmenorrhea treated with ibuprofen (IB) as a standard drug. Pain was assessed by measuring the degree of writhing pain. Serum PGF2α, PGE, and β-endorphin levels were evaluated using ELISA. Hematoxylin-eosin staining was used to examine uterine morphology, such as thickness, vacuolization, and inflammation.
Results
WC had a pain normalization effect comparable to that of ibuprofen. Ibuprofen is superior to both types of cupping in reducing the PGF2α/PGE ratio and the PGF2α to β-endorphins ratio. WC and DC have capabilities comparable to those of ibuprofen in improving uterine vacuolization and inflammation.
Conclusions
These results indicate that WC is more effective than DC in suppressing dysmenorrhea symptoms, modulating the hormone level ratio, and repairing uterine pathology. The potential benefits of cupping provide an opportunity for further studies in human subjects.
{"title":"Effects of wet cupping in a rat model of primary dysmenorrhea","authors":"Sri Lestariningsih , Didik Gunawan Tamtomo , Sri Sulistyowati , Dono Indarto , Soetrisno Soetrisno , Hanik Badriyah Hidayati , Wahyudi Widada","doi":"10.1016/j.jaim.2024.101047","DOIUrl":"10.1016/j.jaim.2024.101047","url":null,"abstract":"<div><h3>Background</h3><div>Primary dysmenorrhea (PD) is characterized by discomfort with no organic etiology (no pelvic disease), recurring pain, or lower abdominal cramps that start between the first 8–72 h of menstruation. Cupping therapy uses a tool to form a vacuum at certain points on the skin.</div></div><div><h3>Objectives</h3><div>We investigated the mechanism of pain relief caused by cupping therapy in primary dysmenorrhea that is played by cupping therapy in PD. This study aimed to investigate the effects of the cupping method on pain symptoms, changes in PGF2α, PGE, and β-endorphin levels, and uterine morphology in PD.</div></div><div><h3>Methods</h3><div>A total of 35 female rats were divided into five groups (n = 7 rats per group): control, PD, dysmenorrhea treated with dry cupping (DC), dysmenorrhea treated with wet cupping (WC), and dysmenorrhea treated with ibuprofen (IB) as a standard drug. Pain was assessed by measuring the degree of writhing pain. Serum PGF2α, PGE, and β-endorphin levels were evaluated using ELISA. Hematoxylin-eosin staining was used to examine uterine morphology, such as thickness, vacuolization, and inflammation.</div></div><div><h3>Results</h3><div>WC had a pain normalization effect comparable to that of ibuprofen. Ibuprofen is superior to both types of cupping in reducing the PGF2α/PGE ratio and the PGF2α to β-endorphins ratio. WC and DC have capabilities comparable to those of ibuprofen in improving uterine vacuolization and inflammation.</div></div><div><h3>Conclusions</h3><div>These results indicate that WC is more effective than DC in suppressing dysmenorrhea symptoms, modulating the hormone level ratio, and repairing uterine pathology. The potential benefits of cupping provide an opportunity for further studies in human subjects.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 6","pages":"Article 101047"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号